First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort

BACKGROUND/AIMS: Aim of this retrospective study was to analyze the efficacy, safety, and predictors of treatment success for first-generation-PI triple therapies, including either boceprevir or telaprevir, in a mono-centric “real-life” setting with respect to SVR 24. PATIENTS: 131 patients (102 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Werner, Christoph R, Franz, Carolin, Egetemeyr, Daniel P, Beck, Robert, Malek, Nisar P, Lauer, Ulrich M, Berg, Christoph P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355422/
https://www.ncbi.nlm.nih.gov/pubmed/25889921
http://dx.doi.org/10.1186/s12985-015-0261-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355422/
https://www.ncbi.nlm.nih.gov/pubmed/25889921
http://dx.doi.org/10.1186/s12985-015-0261-0

Ejemplares similares